Retarding the progression of diabetic nephropathy in type 2 diabetes mellitus: Focus on hypertension and proteinuria

Annals of the Academy of Medicine Singapore

Volumn 34, Issue 1, 2005, Pages 24-30

  Lee, Grace S L ^a,b  

^a SINGAPORE GENERAL HOSPITAL   (Singapore)

^b GLENEAGLES HOSPITAL   (Singapore)

Author keywords

Ace inhibitors; Angiotensin receptor blockers; Microalbuminuria

Indexed keywords

AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; IRBESARTAN; LOSARTAN; NISOLDIPINE; RAMIPRIL; TELMISARTAN; THIAZIDE DIURETIC AGENT; TRANDOLAPRIL; VALSARTAN; VERAPAMIL;

BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CLINICAL TRIAL; DIABETIC NEPHROPATHY; DISEASE COURSE; DISEASE SEVERITY; DOSE RESPONSE; DRUG INDICATION; EDEMA; HEART INFARCTION; HUMAN; HYPERTENSION; HYPOKALEMIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEINURIA; REVIEW; SIDE EFFECT; SOCIOECONOMICS;

EID: 15044342524     PISSN: 03044602     EISSN: 29724066     Source Type: Journal    
DOI: None     Document Type: Review

References (55)

1. World Health Organisation. The Diabetes Program 2004. Available at: http//www.who.int/diabetes/en/. September 21, 2004.
2. Remuzzi G, Schieppati A, Ruggenenti P. Nephropathy in patients with type 2 diabetes. N Engl J Med 2002;346:1145-51.
3. National Health Survey 1998. Singapore: Epidemiology and Disease Control Department, Ministry of Health.
4. Lee G. End-stage renal disease in the Asian-Pacific region. Semin Nephrol 2003;23:107-14.
5. Ismail N, Becker B, Strzelczyk, Ritz E. Renal disease and hypertension in non-insulin-dependent diabetes mellitus. Kidney Int 1999;55:1-28.
6. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001;345: 870-8.
7. Ritz E, Rychlik I, Locatelli F, Halimi S. End-stage renal failure in type 2 diabetes - a medical castratrophe of worldwide dimensions. Am J Kidney Dis 1999;34:795-808.
8. Ritz E. Albuminuria and vascular damage - the vicious twins. N Engl J Med 2003;348:2349-52.
9. Eurich DT, Majumdar SR, Tsuyuki RT, Johnson JA. Reduced mortality associated with the use of ACE inhibitors in patients with type 2 diabetes. Diabetes Care 2004;27:1330-4.
10. Parving HH, Mauer M, Ritz E. Diabetic nephropathy. In: Brenner BM, editor. Brenner & Rector's The Kidney. 7th ed. Vol 2. Philadelphia: Sauders, 2004:1777-818.
11. Ritz E, Stefanski A. Diabetic nephropathy in type II diabetes. Am J Kidney Dis 1996;27:167-94.
12. Parving HH, Gall MA, Skott P, Jorgensen HE, Lokkegaard H, Jorgensen F, et al. Prevalence and causes of albuminuria in non-insulin-dependent diabetic patients. Kidney Int 1992;41:758-62.
13. Keller CK, Bergis KH, Fliser D, Ritz E. Renal findings in patients with short-term type 2 diabetes. J Am Soc Nephrol 1996;12:2627-35.
14. Gaede P, Vedel P, Parving H-H, Pedersen O. Intensified multifactorial intervention in patients with type 2 diabetes mellitus and micro-albuminuria: the Steno type 2 randomised study. Lancet 1999;353: 617-22.
15. Tight blood pressure control and risk of macrovascular and micro vascular complications in type 2 diabetes. UK Prospective Diabetes Study Group; UKPDS 38. BMJ 1998;317:703-13.
16. Snow V, Weiss KB, Mottur-Pilson C; Clinical Efficacy Assessment Subcommittee of the American College of Physicians. The evidence base for tight blood pressure control in the management of type 2 diabetes mellitus. Ann Intern Med 2003;138:587-92.
17. Vijan S, Hayward RA. Treatment of hypertension in type 2 diabetes mellitus: blood pressure goals, choice of agents and setting priorities in diabetes care. Ann Intern Med 2003;138:593-602.
18. Hansson I, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, et al; HOT Study Group. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998;351:1755-62.
19. Khan NA, McAlister FA, Campbell NR, Feldman RD, Rabkin S, Mahon J, et al. The 2004 Canadian recommendations for the management of hypertension: Part II - Therapy. Can J Cardiol 2004;20:41-54.
20. American Diabetes Association. Treatment of hypertension in adults with diabetes. Diabetes Care 2003;26(suppl 1):S80-S82.
21. Kidney Disease Outcomes Quality Initiative CK/DOQI. Clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 2004;43:5(suppl 1):S1-S290.
22. Whitworth JA; World Health Organization (WHO), International Society of Hypertension Writing Group. World Health Organization (WHO), International Society of Hypertension (ISH) statement on management of hypertension. World Health Organization, International Society of Hypertension Writing Group. J Hypertens 2003;21:1983-92.
23. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. The JNC 7 report. JAMA 2003;289:2560-72. Erratum in: JAMA 2003;290:197.
24. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. The JNC 7 report. JAMA 2003;289:2560-72. Erratum in: JAMA 2003;290:197.
25. Abbott K, Basta E, Bakris GL. Blood pressure control and nephroprotection in diabetes. J Clin Pharmacol 2004;44:431-8.
26. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-9.
27. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-60.
28. Sica DA, Schoolwerth AC. Part 1. Uric acid and losartan. Curr Opin Nephrol Hypertens 2002;11:475-82.
29. Monton M, Jimenez A, Nunez A, Loez-Blaya A, Farre J, Gomez J, et al. Comparative effects of angiotensin II AT-1-type receptor antagonists in vitro on human platelet activation. J Cardiovasc Pharmacol 2000;35: 906-13.
30. Nunez A, Gomez J, Zalba LR, Monton M, Jimenez A, Velasco S, et al. Losartan inhibits in vitro platelet activation: comparison with candesartan and valsartan. J Renin Angiotensin Aldosterone Syst 2000;1:175-9.
31. Verma S, Strauss M. Angiotensin receptor blockers and myocardial infarction. BMJ 2004;329:1248-9.
32. Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004;363:2022-31.
33. Is GSK guilty of fraud? Lancet 2004;363:1919.
34. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000;355:253-9. Erratum in: Lancet 2000;356:860.
35. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000;355:253-9. Erratum in: Lancet 2000;356:860.
36. Barnett AH, Bain SC, Bouter P, Karlberg B, Madsbad S, Jervell J, et al. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes with nephropathy. N Engl J Med 2004;351:1952-61.
37. Tatti P, Pahor M, Byington RP, Di Mauro P, Guarisco R, Strollo G, et al. Outcome results of the Fosinopril versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care 1998;21:597-603.
38. Estacio RO, Jeffers BW, Hiatt WR, Biggerstaff SL, Gifford N, Schrier RW. The effects of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med 1998;338:645-52.
39. Grossman E, Messerli FH. Are calcium antagonists beneficial in diabetic patients with hypertension? Am J Med 2004;116:44-9.
40. Owens PE, Lyons S, O'Brien E. Can heart rate predict blood pressure response to anti-hypertensive drug therapy? J Hum Hypertens 1998;12:229-33.
41. Giugliano D, Acampora R, Marfella R, De Rosa N, Ziccardi P, Ragone R, et al. Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension. A randomized, controlled trial. Ann Intern Med 1997;126:955-9.
42. Keane WF, Eknoyan G. Proteinuria, albuminuria, risk, assessment, detection, elimination (PARADE): a position paper of the National Kidney Foundation. Am J Kidney Dis 1999;33:1004-10.
43. Remuzzi G, Bertani T. Pathophysiology of progressive nephropathies. N Engl J Med 1998;339:1448-56.
44. Onuigbo M, Weir MR. Evidence-based treatment of hypertension in patients with diabetes mellitus. Diabetes 2003;5:13-26.
45. Bakris GL, Cooper JB, Vicknair N, Salder R, Leurgans S. Calcium channel blockers vs other anti-hypertensive therapies in the progression of non-insulin-dependent diabetes mellitus associated with nephropathy. Kidney Int 1996;56:1641-50.
46. Bakris GL, Weir MR, DeQuattro V, McMahon FG. Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy. Kidney Int 1998;54:1283-9.
47. Lebowitz HE, Wiegmann TB, Cnaan A, Shahinfar S, Sica DA, Broadstone V, et al. Renal protective effects of enalapril in hypertensive NIDDM: role of baseline albuminuria. Kidney Int Suppl 1994;45:S150-S155.
48. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P; Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001;345: 870-8.
49. Ravid M, Lang R, Rachmani R, Lishner M. Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus: A 7-year follow-up study. Arch Intern Med 1996;156:286-9.
50. Schrier RW, Estacio RO, Esler A, Mehler P. Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int 2002;61:1086-97.
51. Ruggenenti P, Fassi A, Ilieva AP, Bruno S, Iliev IP, Brusegan V, et al; Bergamo Nephrologic Diabetes Complications Trial (BENEDICT) Investigations. Preventing microalbuminuria in type 2 diabetes. New Engl J Med 2004;351:1941-51.
52. Mogensen CE, Neldam S, Tikkanen I, Oren S, Viskoper R, Watts RW, et al. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ 2000;321:1440-4.
53. Rossing K, Christensen PK, Jensen BR, Pavring HH. Dual blockade of the renin-angiotensin system in diabetic nephropathy: a randomized double-blind crossover study. Diabetes Care 2002;25:95-100.
54. Rosenburg ME, Hsu CY. Chronic kidney disease and progression - Renoprotective therapy. NephSAP 2004;3:308-17.
55. Bakris GL, Weir MR. Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern? Arch Intern Med 2000;160:685-93.